神经肌肉疾病与胸廓疾病患者居家与住院启动慢性无创机械通气的随机试验:荷兰Homerun试验
这项荷兰全国多中心随机对照非劣效性试验纳入96例有家庭机械通气指征的神经肌肉疾病或胸廓疾病患者,比较居家(远程监测)与住院启动无创通气。6个月内两组PaCO2均显著改善且组间无显著差异,生活质量多个维度改善且组间无差异,居家组人均社会成本降低超过3200欧元。
要点
- 居家启动无创通气在6个月PaCO2改善方面非劣效于住院启动。
- 两组健康相关生活质量多个维度均改善,组间无显著差异。
- 居家组人均社会成本降低超过3200欧元(3793美元)。
核心结论
- 全国多中心研究显示,居家启动家庭机械通气在气体交换和生活质量改善方面非劣效于住院启动。
- 从患者角度看,居家启动可能更具吸引力,且每例患者6个月内节省超过3200欧元(3793美元)。
研究设计与样本
- 全国性随机对照非劣效性试验,每个家庭机械通气中心招募24例患者(居家组n=12,住院组n=12)。
- 纳入神经肌肉疾病或胸廓疾病且有家庭机械通气指征的患者,共随机96例,多数诊断为神经肌肉疾病。
- 主要结局为6个月内动脉二氧化碳分压(PaCO2)变化,次要结局为生活质量和成本。
主要发现
- 居家组PaCO2从6.1 kPa降至5.6 kPa(P < .01),住院组从6.3 kPa降至5.6 kPa(P < .01),组间无显著差异。
- 健康相关生活质量多个子量表显著改善,但居家组与住院组之间无显著差异。
- 从社会角度看,居家组每例患者成本降低超过3200欧元(3793美元)。
关键数值与推荐
- 主要结局为6个月内PaCO2变化,两组均显著改善且组间无显著差异。
- 居家组PaCO2从6.1 kPa降至5.6 kPa(P < .01)。
- 住院组PaCO2从6.3 kPa降至5.6 kPa(P < .01)。
- 居家组每例患者6个月内社会成本降低超过3200欧元(3793美元)。
临床怎么用
- 对于有家庭机械通气指征的神经肌肉疾病或胸廓疾病患者,可考虑采用远程监测支持下的居家启动策略。
- 居家启动可作为住院启动的替代方式,有助于减少住院床位依赖并降低社会成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an increasing demand for home mechanical ventilation (HMV) in patients with chronic respiratory insufficiency. At present, noninvasive ventilation is exclusively initiated in a clinical setting at all four centers for HMV in the Netherlands. In addition to its high societal costs and patient discomfort, commencing HMV is often delayed because of a lack of hospital bed capacity. RESEARCH QUESTION: Is HMV initiation at home, using a telemonitoring approach, noninferior to in-hospital initiation in a nationwide study? STUDY DESIGN AND METHODS: We conducted a nationwide, randomized controlled noninferiority trial, in which every HMV center recruited 24 patients (home [n = 12] vs hospital [n = 12]) with a neuromuscular disease or thoracic cage disorder, all with an indication to start HMV. Change in arterial CO2 (Paco2) over a 6-month period was considered the primary outcome, and quality of life and costs were assessed as secondary outcomes. RESULTS: A total of 96 patients were randomized, most of them diagnosed with neuromuscular disease. We found a significant improvement in Paco2 within both groups (home: from 6.1 to 5.6 kPa [P < .01]; hospital: from 6.3 to 5.6 kPa [P < .01]), with no significant differences between groups. Health-related quality of life showed significant improvement on various subscales; however, no significant differences were observed between the home and hospital groups. From a societal perspective, a cost reduction of more than €3,200 ($3,793) per patient was evident in the home group. INTERPRETATION: This nationwide, multicenter study shows that HMV initiation at home is noninferior to hospital initiation, as it shows the same improvement in gas exchange and health-related quality of life. In fact, from a patient's perspective, it might even be a more attractive approach. In addition, starting at home saves over €3,200 ($3,793) per patient over a 6-month period. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03203577; URL: www.clinicaltrials.gov.
引用
- van den Biggelaar RJM, Hazenberg A, Cobben NAM, et al. A Randomized Trial of Initiation of Chronic Noninvasive Mechanical Ventilation at Home vs In-Hospital in Patients With Neuromuscular Disease and Thoracic Cage Disorder: The Dutch Homerun Trial. Chest. 2020. PMID: 32682770. doi:10.1016/j.chest.2020.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。